ACM
RLAY icon

Aster Capital Management’s Relay Therapeutics RLAY Stock Holding History

Aster Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10
Closed -$85 – 1252
2025
Q4 		$85 Buy
+10
New +$71 ﹤0.01% 1044
2024
Q4 		– Sell
-13,324
Closed -$94.3K – 1456
2024
Q3 		$94.3K Buy
+13,324
New +$99.5K 0.02% 385

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Aster Capital Management's RLAY Position: Q1 2026 in Review

Aster Capital Management sold out of Relay Therapeutics (RLAY) in Q1 2026, closing a stake of 10 shares — an estimated $85 sold.

Aster Capital Management first reported a position in RLAY in Q3 2024 and held it in 2 quarters. The position peaked at $94.3K in Q3 2024. 244 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

  • Aster Capital Management reported no remaining Relay Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Aster Capital Management sold 10 Relay Therapeutics shares in Q1 2026, an estimated $85.
  • Aster Capital Management first reported a position in Relay Therapeutics in Q3 2024 and held it in 2 quarters.
  • Aster Capital Management's Relay Therapeutics position peaked at $94.3K in Q3 2024.
  • 244 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.